02.09.2022
Prevention
$660,000.00
36 months
Very Early Onset Inflammatory Bowel Disease (VEOIBD): Precision Molecular Diagnoses to Targeted Therapies: Mount Sinai Studies
This grant will develop a novel therapeutic tailored to a subset of CD patients who are refractory to current therapies and will facilitate identification of other investigational drugs for infants, children, and adults with severe forms of IBD.